Drew Moghanaki/X
May 1, 2025, 16:36
Drew Moghanaki: CW pain is rare, and when it occurs always heals
Drew Moghanaki, Chief Medical Officer at Respirati, shared on X a recent paper by Daniel Raymond et al. published in The Journal of Thoracic and Cardiovascular Surgery:
“While radiation oncologists and medical physicists perseverate about the chest wall V30 and 2% risk of pain after lung SBRT, thoracic surgeons are completing randomized clinical trials of lidocaine and bupivacaine with epinephrine (standard of care) vs cryoanalgesia to address the 100% risk of pain that occurs after lung resection.
My approach is to set a CW limit of 105% of the Rx, and make sure the PTV is fully covered otherwise. CW pain is rare, and when it occurs always heals.”
Title: A randomized study of cryoablation of intercostal nerves in patients undergoing minimally invasive thoracic surgery
Authors: Benny Weksler, Conor Maxwell, Lauren Drake, Lawrence Crist, Kara Specht, Pamela Kuchta, Kurt DeHaven, Isabella Weksler, Brent A. Williams, Hiran C. Fernando
You Can Read the Full Article in JTCVS.
Other posts featuring Drew Moghanaki on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 16:36
May 1, 2025, 16:32
May 1, 2025, 16:20
May 1, 2025, 15:20
May 1, 2025, 14:51